Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Merck & Co., Inc.MRK · Entity 2807 | EVP&Pres, Merck Animal Heallth | August 10, 2026 | August 12, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Merck & Co., Inc.
Report date August 10, 2026 · Filed August 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 110,167.07 |
Ending reported balance
After 2026-08-12 transaction · row 5
5 source rows · reconciled sequenceRow 1 · 2026-08-10 · Sale · Disposed 20,784 · Balance 134,703.07 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $130.0000 to $130.9500, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. Row 2 · 2026-08-11 · Sale · Disposed 7,410 · Balance 127,293.07 F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $131.0000 to $131.9800, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. Row 3 · 2026-08-11 · Sale · Disposed 5,427 · Balance 121,866.07 F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $132.0000 to $132.6514, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. Row 4 · 2026-08-12 · Sale · Disposed 11,099 · Balance 110,767.07 F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $131.0000 to $131.9950, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. Row 5 · 2026-08-12 · Sale · Disposed 600 · Balance 110,167.07 F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $132.0000 to $132.0700, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $130.0000 to $130.9500, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $131.0000 to $131.9800, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $132.0000 to $132.6514, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.
F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $131.0000 to $131.9950, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.
F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $132.0000 to $132.0700, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 26, 2021 Filed Mar 2, 2021 16:48 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantCommon Stock | 25,510 | $72.62 | $1,852,536.20 |
DisclosureSEC source: 0001127602-21-008575 · form4.xml · nonDerivative · entry 1 DeLuca Richard R. · CIK 0001421339 · EVP&Pres, Merck Animal Heallth 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,051.694 F1 · shares: Distribution of net after tax shares of common stock on satisfaction of performance criteria for performance share units granted on 3/29/18. Performance shares were paid out at 166 percent of target awards. Includes dividends accrued over the three-year performance period ending December 31, 2020. F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| May 01, 2020 Filed May 5, 2020 20:41 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (Right to Buy) · Derivative | 75,514 | $0.00 Strike: $77.67 | $0.00 |
DisclosureSEC source: 0001127602-20-015445 · form4.xml · derivative · entry 3 DeLuca Richard R. · CIK 0001421339 · EVP&Pres, Merck Animal Heallth 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,514 Underlying: Common Stock · 75,514 shares Expires 2030-04-30 F3 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on 5/1/2021, 5/1/2022 and 5/1/2023. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 22:24 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantCommon Stock | 14,374 | $76.56 | $1,100,473.44 |
DisclosureSEC source: 0001127602-20-009135 · form4.xml · nonDerivative · entry 1 DeLuca Richard R. · CIK 0001421339 · EVP&Pres, Merck Animal Heallth 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,856.868 F1 · shares: Distribution of net after tax shares of common stock on satisfaction of performance criteria for performance share units granted on 3/31/17. Performance shares were paid out at 137 percent of target awards. Includes dividends accrued over the three-year performance period ending December 31, 2019. F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| August 09, 2019 Filed Aug 12, 2019 21:13 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,427 | $0.00 Strike: $39.29 | $0.00 |
DisclosureSEC source: 0001127602-19-026430 · form4.xml · derivative · entry 7 DeLuca Richard R. · CIK 0001421339 · EVP&Pres, Merck Animal Heallth 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,427 shares Expires 2022-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option became exercisable in equal installments on 5/2/2013, 5/2/2014 and 5/2/2015. Read SEC document |
| August 09, 2019 Filed Aug 12, 2019 21:13 UTC | Merck & Co., Inc. MRK · Entity 2807 | SaleCommon Stock | 6,427 | $85.09 | $546,849.65 |
DisclosureSEC source: 0001127602-19-026430 · form4.xml · nonDerivative · entry 4 DeLuca Richard R. · CIK 0001421339 · EVP&Pres, Merck Animal Heallth 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,523.81 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $85.0500 to $85.1450, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| August 09, 2019 Filed Aug 12, 2019 21:13 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 6,427 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-026430 · form4.xml · nonDerivative · entry 3 DeLuca Richard R. · CIK 0001421339 · EVP&Pres, Merck Animal Heallth 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,950.81 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 08, 2019 Filed Aug 12, 2019 21:13 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionStock Option (Right to Buy) · Derivative | 31,699 | $0.00 Strike: $39.29 | $0.00 |
DisclosureSEC source: 0001127602-19-026430 · form4.xml · derivative · entry 6 DeLuca Richard R. · CIK 0001421339 · EVP&Pres, Merck Animal Heallth 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,427 Underlying: Common Stock · 31,699 shares Expires 2022-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option became exercisable in equal installments on 5/2/2013, 5/2/2014 and 5/2/2015. Read SEC document |
| August 08, 2019 Filed Aug 12, 2019 21:13 UTC | Merck & Co., Inc. MRK · Entity 2807 | SaleCommon Stock | 31,699 | $85.01 | $2,694,789.05 |
DisclosureSEC source: 0001127602-19-026430 · form4.xml · nonDerivative · entry 2 DeLuca Richard R. · CIK 0001421339 · EVP&Pres, Merck Animal Heallth 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,523.81 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $85.0000 to $85.0450, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. Read SEC document |
| August 08, 2019 Filed Aug 12, 2019 21:13 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 31,699 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-026430 · form4.xml · nonDerivative · entry 1 DeLuca Richard R. · CIK 0001421339 · EVP&Pres, Merck Animal Heallth 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,222.81 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 03, 2019 Filed May 8, 2019 00:33 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionStock Option (right to buy) · Derivative | 35,000 | $0.00 Strike: $39.29 | $0.00 |
DisclosureSEC source: 0001104659-19-027602 · a4.xml · derivative · entry 5 DeLuca Richard R. · CIK 0001421339 · EVP&Pres, Merck Animal Heallth 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,126 Underlying: Common Stock · 35,000 shares Expires 2022-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option became exercisable in equal installments on 5/2/2013, 5/2/2014 and 5/2/2015. Read SEC document |
| May 03, 2019 Filed May 8, 2019 00:33 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (right to buy) · Derivative | 56,454 | $0.00 Strike: $80.00 | $0.00 |
DisclosureSEC source: 0001104659-19-027602 · a4.xml · derivative · entry 4 DeLuca Richard R. · CIK 0001421339 · EVP&Pres, Merck Animal Heallth 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,454 Underlying: Common Stock · 56,454 shares Expires 2029-05-02 F3 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on 5/3/2020, 5/3/2021 and 5/3/2022. Read SEC document |
| May 03, 2019 Filed May 8, 2019 00:33 UTC | Merck & Co., Inc. MRK · Entity 2807 | SaleCommon Stock | 35,000 | $80.00 | $2,800,000.00 |
DisclosureSEC source: 0001104659-19-027602 · a4.xml · nonDerivative · entry 2 DeLuca Richard R. · CIK 0001421339 · EVP&Pres, Merck Animal Heallth 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,064.209 F1 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| May 03, 2019 Filed May 8, 2019 00:33 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 35,000 | $39.29 | $1,375,150.00 |
DisclosureSEC source: 0001104659-19-027602 · a4.xml · nonDerivative · entry 1 DeLuca Richard R. · CIK 0001421339 · EVP&Pres, Merck Animal Heallth 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,064.209 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 25, 2019 Filed Feb 27, 2019 23:55 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantCommon Stock | 13,507 | $80.38 | $1,085,692.66 |
DisclosureSEC source: 0001225208-19-003892 · doc4.xml · nonDerivative · entry 1 DeLuca Richard R. · CIK 0001421339 · EVP&Pres, Merck Animal Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,584.98 F1 · shares: Distrubtion of net after tax shares of common stock on satisfaction of performance criteria for performance share units granted on 3/31/16. Performance shares were paid out at 126 percent of target awards. Includes dividends accured over the three-year performance period ending December 31, 2018. F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| October 30, 2018 Filed Nov 1, 2018 21:07 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionStock Option (right to buy) · Derivative | 25,467 | $0.00 Strike: $34.19 | $0.00 |
DisclosureSEC source: 0001225208-18-015068 · doc4.xml · derivative · entry 4 DeLuca Richard R. · CIK 0001421339 · EVP&Pres, Merck Animal Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,467 shares Expires 2021-11-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option became exercisable in equal installments on 11/2/2012, 11/2/2013 and 11/2/2014. Read SEC document |
| October 30, 2018 Filed Nov 1, 2018 21:07 UTC | Merck & Co., Inc. MRK · Entity 2807 | SaleCommon Stock | 25,467 | $72.00 | $1,833,738.60 |
DisclosureSEC source: 0001225208-18-015068 · doc4.xml · nonDerivative · entry 2 DeLuca Richard R. · CIK 0001421339 · EVP&Pres, Merck Animal Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,667.828 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $72.0000 to $72.0150, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| October 30, 2018 Filed Nov 1, 2018 21:07 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 25,467 | $34.19 | $870,716.73 |
DisclosureSEC source: 0001225208-18-015068 · doc4.xml · nonDerivative · entry 1 DeLuca Richard R. · CIK 0001421339 · EVP&Pres, Merck Animal Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,134.828 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 04, 2018 Filed May 8, 2018 21:32 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (right to buy) · Derivative | 73,191 | $0.00 Strike: $57.75 | $0.00 |
DisclosureSEC source: 0001225208-18-008934 · doc4.xml · derivative · entry 3 DeLuca Richard R. · CIK 0001421339 · EVP&Pres, Merck Animal Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,191 Underlying: Common Stock · 73,191 shares Expires 2028-05-03 F3 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on 5/4/2019, 5/4/2020 and 5/4/2021. Read SEC document |
| February 27, 2018 Filed Mar 2, 2018 00:33 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantCommon Stock | 12,575 | $54.72 | $688,104.00 |
DisclosureSEC source: 0001225208-18-005016 · doc4.xml · nonDerivative · entry 1 DeLuca Richard R. · CIK 0001421339 · EVP&Pres, Merck Animal Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,380.841 F1 · shares: Distribution of net after tax shares of common stock on satisfaction of performance criteria for performance share units granted on 3/31/15. Performance shares were paid out at 138 percent of target awards. Includes dividends accrued over the three-year performance period ending December 31, 2017. F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| February 09, 2018 Filed Feb 9, 2018 21:48 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionRestricted Stock Unit · Derivative | 8,572 | $54.73 | $469,145.56 |
DisclosureSEC source: 0001225208-18-002429 · doc4.xml · derivative · entry 4 DeLuca Richard R. · CIK 0001421339 · EVP&Pres, Merck Animal Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,572 shares Expires 2018-02-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. Read SEC document |
| February 09, 2018 Filed Feb 9, 2018 21:48 UTC | Merck & Co., Inc. MRK · Entity 2807 | Tax withholdingCommon Stock | 2,974 | $54.73 | $162,767.02 |
DisclosureSEC source: 0001225208-18-002429 · doc4.xml · nonDerivative · entry 2 DeLuca Richard R. · CIK 0001421339 · EVP&Pres, Merck Animal Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,805.841 F1 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| February 09, 2018 Filed Feb 9, 2018 21:48 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 8,572 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-002429 · doc4.xml · nonDerivative · entry 1 DeLuca Richard R. · CIK 0001421339 · EVP&Pres, Merck Animal Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,779.841 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 05, 2017 Filed May 9, 2017 20:42 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (right to buy) · Derivative | 64,194 | $0.00 Strike: $63.97 | $0.00 |
DisclosureSEC source: 0001225208-17-009432 · doc4.xml · derivative · entry 3 DeLuca Richard R. · CIK 0001421339 · EVP&Pres, Merck Animal Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,194 Underlying: Common Stock · 64,194 shares Expires 2027-05-04 F3 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on 5/5/2018, 5/5/2019 and 5/5/2020. Read SEC document |
| February 27, 2017 Filed Mar 1, 2017 21:46 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantCommon Stock | 11,771 | $65.85 | $775,120.35 |
DisclosureSEC source: 0001225208-17-005084 · doc4.xml · nonDerivative · entry 1 DeLuca Richard R. · CIK 0001421339 · EVP&Pres, Merck Animal Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,090.026 F1 · shares: Distribution of net after tax shares of common stock on satisfaction of performance criteria for performance share units granted on 3/31/14. Performance shares were paid out at 158 percent of target awards. Includes dividends accrued over the three-year performance period ending December 31, 2016. F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| May 10, 2016 Filed May 12, 2016 15:39 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (right to buy) · Derivative | 101,868 | $0.00 Strike: $54.68 | $0.00 |
DisclosureSEC source: 0001225208-16-033204 · doc4.xml · derivative · entry 3 DeLuca Richard R. · CIK 0001421339 · EVP&Pres, Merck Animal Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,868 Underlying: Common Stock · 101,868 shares Expires 2026-05-09 F3 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on 5/10/2017, 5/10/2018 and 5/10/2019. Read SEC document |
| February 22, 2016 Filed Feb 24, 2016 17:37 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantCommon Stock | 11,332 | $50.77 | $575,325.64 |
DisclosureSEC source: 0001225208-16-027758 · doc4.xml · nonDerivative · entry 1 DeLuca Richard R. · CIK 0001421339 · EVP&Pres, Merck Animal Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,583.479 F1 · shares: Distribution of net after tax shares of common stock on satisfaction of performance share units granted on 03/29/2013. Performance shares were paid out at 105 percent of target awards. F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| May 02, 2015 Filed May 5, 2015 20:46 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionRestricted Stock Unit · Derivative | 5,090 | $59.86 | $304,687.40 |
DisclosureSEC source: 0001225208-15-011273 · doc4.xml · derivative · entry 5 DeLuca Richard R. · CIK 0001421339 · EVP&Pres, Merck Animal Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,090 shares Expires 2015-05-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. Read SEC document |
| May 02, 2015 Filed May 5, 2015 20:46 UTC | Merck & Co., Inc. MRK · Entity 2807 | Tax withholdingCommon Stock | 2,640 | $59.86 | $158,030.40 |
DisclosureSEC source: 0001225208-15-011273 · doc4.xml · nonDerivative · entry 2 DeLuca Richard R. · CIK 0001421339 · EVP&Pres, Merck Animal Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,924.323 F1 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| May 02, 2015 Filed May 5, 2015 20:46 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 5,090 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-15-011273 · doc4.xml · nonDerivative · entry 1 DeLuca Richard R. · CIK 0001421339 · EVP&Pres, Merck Animal Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,564.323 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 01, 2015 Filed May 5, 2015 20:46 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (right to buy) · Derivative | 86,687 | $0.00 Strike: $59.86 | $0.00 |
DisclosureSEC source: 0001225208-15-011273 · doc4.xml · derivative · entry 4 DeLuca Richard R. · CIK 0001421339 · EVP&Pres, Merck Animal Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,687 Underlying: Common Stock · 86,687 shares Expires 2025-04-30 F3 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on 5/1/2016, 5/1/2017 and 5/1/2018. Read SEC document |
| February 23, 2015 Filed Feb 25, 2015 16:27 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantCommon Stock | 6,649 | $58.30 | $387,636.70 |
DisclosureSEC source: 0001225208-15-005603 · doc4.xml · nonDerivative · entry 1 DeLuca Richard R. · CIK 0001421339 · EVP&Pres, Merck Animal Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,401 F1 · shares: Distribution of net after tax shares of common stock on satisfaction of performance criteria for performance share units granted on 03/30/2012. Performance shares were paid out at 102 percent of target awards. Read SEC document |
| February 09, 2015 Filed Feb 11, 2015 22:25 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantRestricted Stock Unit · Derivative | 8,572 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-15-003596 · doc4.xml · derivative · entry 3 DeLuca Richard R. · CIK 0001421339 · EVP&Pres, Merck Animal Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,572 Underlying: Common Stock · 8,572 shares Expires 2018-02-09 F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. Read SEC document |
| November 02, 2014 Filed Nov 3, 2014 21:46 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionRestricted Stock Unit · Derivative | 4,387 | $57.94 | $254,182.78 |
DisclosureSEC source: 0001225208-14-022447 · doc4.xml · derivative · entry 4 DeLuca Richard R. · CIK 0001421339 · EVP&Pres, Merck Animal Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,387 shares Expires 2014-11-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. Read SEC document |
| November 02, 2014 Filed Nov 3, 2014 21:46 UTC | Merck & Co., Inc. MRK · Entity 2807 | Tax withholdingCommon Stock | 1,635 | $57.94 | $94,731.90 |
DisclosureSEC source: 0001225208-14-022447 · doc4.xml · nonDerivative · entry 2 DeLuca Richard R. · CIK 0001421339 · EVP&Pres, Merck Animal Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,752 Read SEC document |
| November 02, 2014 Filed Nov 3, 2014 21:46 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 4,387 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-14-022447 · doc4.xml · nonDerivative · entry 1 DeLuca Richard R. · CIK 0001421339 · EVP&Pres, Merck Animal Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,387 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 09, 2014 Filed May 13, 2014 19:53 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (right to buy) · Derivative | 60,523 | $0.00 Strike: $58.22 | $0.00 |
DisclosureSEC source: 0001225208-14-012817 · doc4.xml · derivative · entry 2 DeLuca Richard R. · CIK 0001421339 · EVP&Pres, Merck Animal Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,523 Underlying: Common Stock · 60,523 shares Expires 2024-05-08 F2 · derivative.exercise_date: The option vests in three equal annual installments beginning May 9, 2015. Read SEC document |
| May 06, 2013 Filed May 8, 2013 23:29 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (right to buy) · Derivative | 70,853 | $0.00 Strike: $44.98 | $0.00 |
DisclosureSEC source: 0001225208-13-011737 · doc4.xml · derivative · entry 2 DeLuca Richard R. · CIK 0001421339 · EVP&Pres, Merck Animal Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,853 Underlying: Common Stock · 70,853 shares Expires 2023-05-05 F2 · derivative.exercise_date: The option vests in three equal annual installments beginning May 6, 2014. Read SEC document |
| May 02, 2012 Filed May 4, 2012 13:39 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (right to buy) · Derivative | 73,126 | $0.00 Strike: $39.29 | $0.00 |
DisclosureSEC source: 0001225208-12-011182 · doc4.xml · derivative · entry 3 DeLuca Richard R. · CIK 0001421339 · EVP&Pres, Merck Animal Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,126 Underlying: Common Stock · 73,126 shares Expires 2022-05-01 F3 · derivative.exercise_date: The option vests in three equal annual installments beginning May 2, 2013. Read SEC document |
| May 02, 2012 Filed May 4, 2012 13:39 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantRestricted Stock Unit · Derivative | 5,090 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-12-011182 · doc4.xml · derivative · entry 2 DeLuca Richard R. · CIK 0001421339 · EVP&Pres, Merck Animal Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,090 Underlying: Common Stock · 5,090 shares Expires 2015-05-02 F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. Read SEC document |
| November 02, 2011 Filed Nov 3, 2011 19:16 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (right to buy) · Derivative | 25,467 | $0.00 Strike: $34.19 | $0.00 |
DisclosureSEC source: 0001225208-11-024259 · doc4.xml · derivative · entry 2 DeLuca Richard R. · CIK 0001421339 · EVP&Pres, Merck Animal Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,467 Underlying: Common Stock · 25,467 shares Expires 2021-11-01 F2 · derivative.exercise_date: The option vests in three equal installments beginning 11/02/12. Read SEC document |
| November 02, 2011 Filed Nov 3, 2011 19:16 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantRestricted Stock Unit · Derivative | 4,387 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-11-024259 · doc4.xml · derivative · entry 1 DeLuca Richard R. · CIK 0001421339 · EVP&Pres, Merck Animal Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,387 Underlying: Common Stock · 4,387 shares Expires 2014-11-02 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.